Evidence map›Paper›PMID 32350692›Full record

ArticleJournal of biomolecular NMR2020

Protein NMR of biologicals: analytical support for development and marketed products.

Fabio Casagrande, Klara Dégardin, Alfred Ross

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biomolecular NMR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. NMR in pharmaceutical discovery and development.Journal of biomolecular NMR · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Fabio CasagrandeRoche Pharmaceutical Research & Early Development, Lead Discovery, Roche Innovation Center Basel, Basel, Switzerland. fabio.casagrande@roche.com.ORCID http://orcid.org/0000-0003-1765-6404
Klara DégardinRoche Pharmaceutical Quality Control for Commercial Bulk Products, Complaints and Counterfeits Group, Kaiseraugst, Switzerland.
Alfred RossRoche Pharmaceutical Research & Early Development, Pre-Clinical CMC, Roche Innovation Center Basel, Basel, Switzerland.
Roche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Application of NMR spectroscopy to derive in-depth characterization of structure and dynamical properties of biomolecules is well established nowadays in many laboratories. Most of these methods rest on the availability of protein labeled with stable isotopes like

Indexed as

Antibodies, MonoclonalBiosimilar PharmaceuticalsDrug DevelopmentNuclear Magnetic Resonance, BiomolecularOxidation-ReductionPolyethylene GlycolsProtein Processing, Post-TranslationalProteinsAntibodies, MonoclonalBiosimilar PharmaceuticalsPolyethylene GlycolsProteinsBiologicalsBiosimilarsCounterfeitsHigher order structureNMR

Identifiers

PMID32350692
OpenAlexW3023349161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.